Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Accumulated Expenses (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Accumulated Expenses for 7 consecutive years, with $9.6 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 22.01% to $9.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.6 million through Dec 2025, down 22.01% year-over-year, with the annual reading at $9.6 million for FY2025, 22.01% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $9.6 million at Pliant Therapeutics, up from $8.2 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $20.3 million in Q3 2022, with the low at $4.7 million in Q1 2023.
  • Average Accumulated Expenses over 5 years is $9.4 million, with a median of $8.3 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses surged 307.79% in 2021, then plummeted 61.13% in 2023.
  • Over 5 years, Accumulated Expenses stood at $6.1 million in 2021, then skyrocketed by 41.4% to $8.7 million in 2022, then increased by 18.03% to $10.2 million in 2023, then increased by 20.88% to $12.4 million in 2024, then decreased by 22.01% to $9.6 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $9.6 million, $8.2 million, and $7.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.